HILS vs. VIRI, WHWK, PYRGF, AADI, ATNM, NBRV, OSTX, ELYM, NNVC, and EGRX
Should you be buying Hillstream BioPharma stock or one of its competitors? The main competitors of Hillstream BioPharma include Virios Therapeutics (VIRI), Whitehawk Therapeutics (WHWK), PyroGenesis Canada (PYRGF), Aadi Bioscience (AADI), Actinium Pharmaceuticals (ATNM), Nabriva Therapeutics (NBRV), OS Therapies (OSTX), Eliem Therapeutics (ELYM), NanoViricides (NNVC), and Eagle Pharmaceuticals (EGRX).
Hillstream BioPharma vs. Its Competitors
Hillstream BioPharma (NASDAQ:HILS) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.
13.4% of Hillstream BioPharma shares are owned by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are owned by institutional investors. 30.2% of Hillstream BioPharma shares are owned by insiders. Comparatively, 12.2% of Virios Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Hillstream BioPharma has a beta of 3.08, indicating that its stock price is 208% more volatile than the S&P 500. Comparatively, Virios Therapeutics has a beta of 1.58, indicating that its stock price is 58% more volatile than the S&P 500.
Virios Therapeutics has a consensus target price of $5.00, indicating a potential upside of 5.71%. Given Virios Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Virios Therapeutics is more favorable than Hillstream BioPharma.
Virios Therapeutics' return on equity of -130.33% beat Hillstream BioPharma's return on equity.
In the previous week, Hillstream BioPharma's average media sentiment score of 0.00 equaled Virios Therapeutics'average media sentiment score.
Virios Therapeutics is trading at a lower price-to-earnings ratio than Hillstream BioPharma, indicating that it is currently the more affordable of the two stocks.
Summary
Virios Therapeutics beats Hillstream BioPharma on 6 of the 10 factors compared between the two stocks.
Get Hillstream BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for HILS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding HILS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hillstream BioPharma Competitors List
Related Companies and Tools
This page (NASDAQ:HILS) was last updated on 7/26/2025 by MarketBeat.com Staff
